The $175 million series D financing is expected to help accelerate the clinical development and commercialization of 4C Medical's next-generation transcatheter mitral valve replacement technology.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,